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 2 
To the Editor,  35 
 36 
Asthma is a chronic heterogeneous inflammatory airway disease. Its treatment includes 37 
bronchodilators and anti-inflammatory medication such as corticosteroids. Corticosteroids reduce 38 
transcription of AP-1 and NF-kB and hence may affect DNA methylation. Epigenetics refers to 39 
changes in DNA that can affect transcription, such as methylation of a cytosine nucleotide beside a 40 
guanine nucleotide (CpGs). 41 
 42 
Asthma is associated with differentially methylated CpGs in specific genes [1, 2]. In the largest 43 
study to date, asthmatic children had significantly lower blood methylation levels at 14 CpGs 44 
compared to controls [3]. One previous study found 19 CpGs that were differentially methylated in 45 
blood during systemic corticosteroid exposure in patients with COPD [4]. Possible effects of 46 
inhaled asthma medication on peripheral blood methylation profiles are currently unknown.  47 
 48 
Our aim was to study the association between inhaled corticosteroids and DNA methylation in 49 
peripheral blood cells in children with asthma. First, we performed an epigenome-wide association 50 
study (EWAS) investigating the effects of variable inhaled corticosteroid exposure on DNA 51 
methylation in 8-year-olds with diagnosed asthma in the BAMSE (Barn/Child, Allergy, Milieu, 52 
Stockholm, Epidemiology) cohort followed by replication attempts. Second, using a candidate gene 53 
approach, we evaluated if identified CpGs from the systemic steroid study [4] and the largest 54 
asthma study to date [3], in total 33 CpGs, were differentially methylated in relation to inhaled 55 
asthma treatment.  56 
 57 
BAMSE is a Swedish prospective birth cohort study [5]. A total of 4089 children born 1994-1996 58 
enrolled and information was collected in repeated questionnaires. Blood samples were taken at the 59 
8- and 16-year follow-ups (n=2480; 61 % and n=2547; 62 %, respectively) [6]. For the present 60 
study, we included all subjects with a doctor’s diagnosis of asthma ever up to 8 years and with 61 
DNA methylation data available for analyses (n=215) [3]. Subjects were grouped based on 62 
exposure established in the questionnaires: any medication for breathing difficulties (n=130), any 63 
inhaled corticosteroids or combination medication for any period of time (n=107), and inhaled 64 
corticosteroids continuously (at least 2 consecutive months) (n=39), all in the last 12 months. 65 
STOPPA (Swedish Twin Study on Prediction and Prevention of Asthma), a cohort study of twins 66 
aged 9-14 years [7] was used for replication analyses, and a subset of BAMSE 16-year cohort 67 
 3 
(n=96 cases) was used for additional look-up (Tables E1-2). The regional ethics committee in 68 
Stockholm approved the studies, and written consent was obtained from all parents.  69 
             70 
Robust linear regression was used for the analysis. The reference group comprised subjects 71 
diagnosed with asthma without any asthma medication in the last 12 months (n=85). We applied the 72 
Benjamini-Hochberg method to control the false discovery rate (FDR) at 5 %. P values below FDR 73 
were considered statistically significant in EWAS. Analyses were performed separately in BAMSE 74 
and STOPPA followed by fixed-effects meta-analysis using METAL.  75 
 76 
Beta value was a dependent variable and each mode of asthma medication was a binary independent 77 
variable. Each model was adjusted for sex, age, sensitization to airborne allergens at 8 years, 78 
wheezing in the last 12 months, mother’s smoking at least 1 cigarette per day at baseline and/or 79 
during pregnancy, bisulfite treatment date, and estimated cell types according to the Houseman 80 
method [6] (Table 1). Similar subject groupings and identical models were applied in STOPPA and 81 
BAMSE 16-year analyses.  82 
 83 
Table 1. Distribution of background characteristics of BAMSE subjects with DNA methylation data 84 
measured at 8 years of age in relation to type of asthma treatment. Results shown as n (%), compared to the 85 
total number of subjects in each group. 86 
 Diagnosed asthma 
(n=215) 
Asthma treatment 
  Any medication for 
diagnosed asthma 
(n=130) 
Any inhaled 
corticosteroid 
treatment (n=107) 
Continuous inhaled 
corticosteroid 
treatment (n=39) 
Male 134 (62 %) 83 (64 %) 68 (64 %) 28 (72 %) 
Age in years (mean, SD) 8.1, 0.4 8.1, 0.4 8.1, 0.4 8.1, 0.4 
Sensitization† 106 (49 %) 79 (61 %) 66 (62 %) 28 (72 %) 
At least 1 episode of 
wheezing in the past 12 
months 
104 (48 %) 96 (74 %) 83 (78 %) 31 (79 %) 
Either parent smoked at 
the time of the 8-year 
questionnaire 
46 (21 %) 22 (17 %) 20 (19 %) 6 (15 %) 
Mother's smoking‡ 34 (16 %) 14 (11 %) 12 (11 %) 3 (8 %) 
Socioeconomic status at 
baseline, § blue collar 
worker compared to white 
collar worker  
35  
(16 %) 
180 
(84 %) 
23 
(18 %) 
107 
(82 %) 
20 
(19 %) 
87 
(81 %) 
9 
(23 %) 
30 
(77 %) 
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One or both parents' 
asthma/hay fever/ allergy¶ 
101 (47 %) 65 (50 %) 55 (51 %) 21 (54 %) 
† Sensitization is defined as an IgE antibody level of 0.35 kUA/L or greater against any inhalant allergen at age 8.  87 
‡ The child’s mother smoked at least 1 cigarette per day at any point of time during the pregnancy and/or at the time of 88 
questionnaire 0 (median age of 2 months). 89 
§Socioeconomic status for the household at the time of questionnaire 0, according to dominance order in two classes. 90 
¶ Mother and/or father with doctor’s diagnosis of asthma and asthma medication and/or doctor’s diagnosis of hay fever 91 
in combination with furred pets- and/or pollen allergy at the time of questionnaire 0. 92 
 93 
In total, methylation at 24 individual CpGs was significantly associated at FDR level with asthma 94 
treatment in BAMSE (Table 2; Figures E1-3). However, none of these EWAS hits was nominally 95 
significant in the replication study STOPPA or in BAMSE 16-year-olds, and in the meta-analysis, 96 
none of the CpGs reached genome-wide significance (FDR). As a sensitivity analysis, we repeated 97 
regression analyses in BAMSE 8-year-olds, not adjusting for cell types, and found overall very 98 
consistent results comparing the regression coefficients in the models with and without cell type 99 
adjustment (Table 2).  100 
 101 
Table 2. Statistically significant CpGs (defined as p value below respective FDR) from epigenome-wide 102 
association study analyses of any asthma medication, any corticosteroid medication, and continuous 103 
corticosteroid medication exposure in the last 12 months and DNA methylation change in peripheral blood 104 
cells from Swedish 8-year-olds. Total sum of subjects included in each group is stated after the exposure type 105 
(n). FDR for all is 2,2E-06. “-“indicates missing value as these CpGs were not included in the STOPPA 106 
DNA methylation data after normalization. See appendix for further description.  107 
 108 
CpG site Gene†  Distance 
(bp) ‡  
Coefficient, 
BAMSE 8§  
p value, 
BAMSE 
8 
p value, 
STOPPA 
p value, 
Meta 
analysis* 
 
p value, 
BAMSE 
16 
Coefficient
BAMSE 8: 
no cell 
adjustment
¶ 
p value, 
BAMSE 8: 
no cell 
adjustment 
Any asthma medication exposure, n=130 
cg25214924 AK058
177 
-42380 -0.016 2.5E-08 0.29 2.6E-03 0.62 -0.013 1.0E-05 
cg03877376 TBX5 85 0.008 2.0E-07 - - 0.64 0.007 7.3E-06 
cg20423602 
ADARB
2-AS1 -8232 -0.014 5.5E-07 0.13 1.5E-06 0.21 -0.012 1.2E-05 
cg15954046 LMNA 303 -0.012 5.5E-07 0.60 1.9E-04 0.51 -0.006 6.8E-02 
cg23966329 UBE2G
1 
-162 -0.003 1.3E-06 0.34 7.4E-03 0.89 -0.003 1.1E-06 
cg14063914 SERAC
1 
349 -0.007 1.7E-06 0.45 4.3E-04 0.72 -0.008 7.3E-08 
cg21731304 
NMNA
T3 -212 -0.021 2.0E-06 0.49 3.3E-05 0.15 -0.021 4.3E-06 
Any corticosteroid exposure, n=107 
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cg16048421 
LOC33
8579 0 0.014 3.9E-07 0.80 7.2E-04 0.29 0,015 7,2E-07 
cg15115986 C1orf1
12 
-20 -0.004 4.9E-07 - - 0.48 -0,004 2,7E-07 
cg03877376 TBX5 85 0.008 5.5E-07 - - 0.68 0,007 1,2E-05 
cg03146079 ADD1 0 -0.005 5.9E-07 0.32 1.6E-06 0.99 -0,005 7,4E-07 
cg17629264 
MAPK
8IP2 -390 -0.021 6.1E-07 0.34 1.5E-05 0.18 -0,014 4,3E-03 
cg24144651 
BC043
227 
-560 -0.009 8.8E-07 - - 0.18 -0,006 2,8E-03 
cg00025044 ERCC6 -1952 -0.011 1.0E-06 0.19 3.7E-05 0.42 -0,015 1,2E-08 
cg25745861 TMEM
54 
-2782 0.012 1.1E-06 0.46 1.5E-05 0.85 0,016 5,8E-08 
cg14136328 SYT1 -69884 -0.013 1.1E-06 0.32 1.4E-03 0.43 -0,010 5,8E-05 
cg18046087 KLC2 0 -0.006 1.1E-06 0.76 4.9E-05 0.87 -0,007 3,9E-08 
cg03043078 MMP1
7 
2420 -0.006 2.0E-06 0.99 4.0E-05 0.23 -0,006 1,3E-06 
Continuous corticosteroid exposure, n=39 
cg07665222 ACRV1 -1393 -0.022 3.3E-07 0.28 3.8E-06 0.75 -0,018 2,3E-04 
cg03877376 TBX5 85 0.010 9.4E-07 - - 0.94 0,009 2,2E-05 
cg22997262 
LOC10
012853
1 
-2329 0.017 1.1E-06 0.43 9.5E-03 0.54 0,018 9,2E-09 
cg15074789 EPHA2 0 -0.008 1.2E-06 - - 0.96 -0,008 9,4E-06 
cg13688889 FOXE1 -6829 -0.048 1.4E-06 0.72 3.1E-04 0.20 -0,049 1,6E-06 
cg00947413 
MIR36
79 -99303 -0.044 1.8E-06 0.22 1.4E-05 0.26 -0,046 1,0E-07 
cg26281051 
DEFB1
29 -95 -0.018 2.0E-06 0.46 2.9E-04 0.30 -0,017 1,3E-04 
cg25745861 TMEM
54 
-2782 0.016 2.6E-06 0.71 1.4E-03 0.54 0,018 9,8E-06 
cg13492223 FUT6 -159 0.017 2.9E-06 0.81 6.0E-04 0.98 0,019 4,6E-04 
†, ‡ Gene annotation according to Illumina450K. CpGs were annotated using the IlluminaHumanMethylation450k.db R 109 
package, with enhanced annotation for nearest genes within 10Mb of each site, as previously described [8]. 110 
§ Regression coefficient, adjusted for sex, age, sensitization to airborne allergens at 8 years, wheezing in the last 12 111 
months, mother’s smoking at least 1 cigarette per day at baseline and/or during pregnancy, bisulfite treatment date, and 112 
estimated cell types. Reference group includes subjects without any asthma medication.  113 
*Meta-analysis of results in BAMSE 8-year-old cohort and STOPPA using a fixed-effects model weighted by the 114 
inverse of the variance using METAL. BAMSE 16-year-olds were not included in the meta-analysis due to overlap with 115 
BAMSE 8 data. 116 
¶ Regression coefficient, adjusted for sex, age, sensitization to airborne allergens at 8 years, wheezing in the last 12 117 
months, mother’s smoking at least 1 cigarette per day at baseline and/or during pregnancy, and bisulfite treatment date. 118 
Reference group includes subjects without any asthma medication. 119 
 120 
Next, we investigated possible DNA methylation changes in the 33 selected CpGs from the 121 
literature [3], [4]. Three CpGs were nominally significant in BAMSE 8-year-olds when comparing 122 
any corticosteroid exposure to no medication and six CpGs showed nominally significant 123 
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methylation increases in relation to continuous corticosteroid exposure with three CpGs increasing 124 
≥1%. However, none of the CpGs survived multiple testing adjustment (Tables E3-5). We 125 
investigated the 33 candidate CpGs in a subset of BAMSE 16-year-olds with an asthma diagnosis 126 
through identical analyses and congruently found no FDR-significant associations with asthma 127 
treatment.  128 
 129 
In summary, several CpGs in EWAS were found differentially methylated in BAMSE at the FDR 130 
genome-wide significance level and results were very similar in models with and without cell-type 131 
adjustment. However, none of these CpGs replicated even at a nominal significance level in 132 
STOPPA or BAMSE 16-year cohort, and after meta-analyses, none of the CpGs survived multiple 133 
test adjustment. Thus, our study does not find evidence for DNA methylation changes in relation to 134 
inhaled asthma treatment, although changes through other epigenetic mechanisms cannot be ruled 135 
out. Our results are based on an observational study and hence do not produce intention-to-treat 136 
results. There are some limitations: firstly, we could not completely adjust for severity of asthma as 137 
the severity is reflected in the medication mode itself. Secondly, in the 8-year follow-up we did not 138 
enquire about systemic steroid use and hence there may be subjects that have used systemic 139 
corticosteroids in the “any medication” group. Thirdly, heterogeneity between the BAMSE and 140 
STOPPA cohorts unlikely explains the lack of replication as both cohorts are from areas with 141 
similar lifestyle factors, ethnic background and sensitization patterns, although more mothers 142 
smoked during pregnancy in BAMSE and more parents in STOPPA had asthma, hay fever or 143 
allergies.  144 
 145 
Furthermore, we explored potential treatment–methylation associations using a candidate gene 146 
approach. We selected CpGs that were found robustly associated with asthma (per se) in the large 147 
study by Xu et al [3], where the authors did not specifically investigate potential influence from 148 
medication. We found a handful nominally associated CpGs with increased methylation in 149 
peripheral blood cells, whereas for asthma, Xu et al reported consistently lower methylation levels. 150 
However, none survived multiple test adjustment in our study.   151 
 152 
There are well-known side effects from long-term systemic corticosteroid treatment, and the study 153 
by Wan et al found DNA methylation differences in COPD patients associated with systemic 154 
steroid use [4]. By exploring the top CpGs from Wan et al, we found no significant methylation 155 
differences in children and adolescents with asthma associated with inhaled corticosteroid 156 
 7 
treatment. However, it should be noted that Wan et al studied adult COPD patients and we included 157 
children and adolescents with asthma in our study. 158 
 159 
In conclusion, we found no evidence that inhaled corticosteroids or other asthma medications affect 160 
peripheral blood cell DNA methylation levels to any major extent, although smaller effects cannot 161 
be excluded.  162 
 163 
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